AT&T and its employee benefit trust have sued dozens of generic drug manufacturers in U.S. federal court, accusing them of engaging in a price-fixing scheme that harmed consumers and the healthcare system. The complaint alleges that competing companies conspired to raise and maintain prices for a range of generic medicines, leveraging parallel behavior and evidence of coordination to suppress competition. AT&T contends that the conduct violated federal antitrust laws and harmed both the company’s employee benefits program and plan participants. The plaintiffs seek treble damages, along with injunctive relief to stop the allegedly unlawful practices and to restore competitive conditions in the generic drug market.
More News
- November routes roundup: Etihad launches flights to Tokyo with A380s
- Flames vs. Mammoth Prediction, Odds, Picks - Dec. 6
- Novartis expands India development hubs as global pipeline grows
- Career Search | Novartis
- Etihad’s A380 will fly to Tokyo in summer 2026
- High-risk Early Breast Cancer Patients in Quebec Left Behind by Recent INESSS Recommendation
- Video. Hundreds of roe deer rescued from Siberian frozen lakes
- AT&T sues generic drugmakers over alleged price-fixing scheme
- Innovating for America: New RLT Site
- Flames 2-0 Mammoth (7 Dec, 2025) Final Score